In the absence of an available murine CML model that can be used in the HLA transgenic mice we tested the efficacy of this combination in in vivo tumour challenge experiments, wherein a pre-defined dose of the modified hB16/HAGE+/Luc+ cells, which also endogenously express WT1, was injected subcutaneously as a “Proof-of-Concept” to form tumour. The gene discussed is WT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.